Abstracts Archive - Page 558 of 2425 - ACR Meeting Abstracts

Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Tali Eviatar¹, Stanley Niznik², Nancy Agmon-Levin² and Daphna Paran³, ¹Tel Aviv Sourasky Medical Center, Givataim, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
Abstract Number: 0086 • ACR Convergence 2021
SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review
Richard Conway¹, Alyssa Grimshaw², Maximilian Konig³, Michael Putman⁴, Ali Duarte-Garcia⁵, Candice Low⁶, Shangyi Jin⁷, Diego Cabrera⁸, Yu Pei Eugenia Chock⁹, Berk Degirmenci¹⁰, Eimear Duff¹¹, Bugra Egeli¹², Elizabeth Graef¹³, Akash Gupta¹⁴, Patricia Harkins¹⁵, Bimba Franziska Hoyer¹⁶, Aruni Jayatilleke¹⁷, Christopher Kasia¹⁸, Aneka Khilnani¹⁹, Adam Kilian²⁰, Alfred Kim²¹, Chung Mun Alice Lin²², Laurie Proulx²³, Sebastian Sattui²⁴, Namrata Singh²⁵, Jeffrey Sparks²⁶, Herman Tam²⁷, Leslie Yingzhijie Tseng², Manuel Ugarte-Gil²⁸, Natasha Ung²⁹, Leanna Wise³⁰, Ziyi Yang³¹, Kristen Young³², Jean Liew³³, Rebecca Grainger³⁴, Zachary Wallace³⁵ and Evelyn Hsieh², ¹St. James's University Hospital, Dublin, Ireland, ²Yale School of Medicine, New Haven, CT, ³The Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical College of Wisconsin, Brookfield, WI, ⁵Mayo Clinic, Rochester, MN, ⁶St. Vincent's University Hospital, Dublin, Ireland, ⁷Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁸Yale School of Medicine, Lima, Peru, ⁹Yale School of Medicine, Greenwich, CT, ¹⁰St. Elizabeth's Medical Center, Boston, MA, ¹¹St. James's Hospital, Dublin, Ireland, ¹²Boston Children's Hospital, Boston, MA, ¹³Emerson Hospital, Concord, MA, ¹⁴Department of Medicine, Yale University School of Medicine, New Haven, CT, ¹⁵St James hospital, Dublin, Ireland, ¹⁶Universittsklinikum Schleswig-Holstein, Kiel, Germany, ¹⁷Temple University, Philadelphia, PA, ¹⁸The Medical College of Wisconsin, Maywood, IL, ¹⁹George Washington University School of Medicine and Health Sciences, Washington, DC, ²⁰George Washington University, Melbourne, FL, ²¹Washington University School of Medicine, St. Louis, MO, ²²Newcastle University, Newcastle, United Kingdom, ²³Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ²⁴Hospital for Special Surgery, New York, NY, ²⁵University of Washington, Bellevue, WA, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ²⁸Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²⁹New South Wales Health, Sydney, Australia, ³⁰LAC+USC/Keck Medicine of USC, Pasadena, CA, ³¹Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing 100730, China, Beijing, China (People's Republic), ³²University of Texas Southwestern Medical Center, Dallas, TX, ³³Boston University, Boston, MA, ³⁴University of Otago, Wellington, New Zealand, ³⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The relative risk of COVID-19 among patients with rheumatic and musculoskeletal disease (RMD) and the comparative severity of COVID-19 infection in RMD remain uncertain.…
Abstract Number: 0089 • ACR Convergence 2021
SARS-CoV-2 Seroprevalence and Seroconversion in a Systemic Lupus Erythematosus Cohort and Comparison to General Population Controls
Hannah Mathew¹, May Choi², Katherine Buhler¹, Ann Clarke¹, Xenia Gukova¹, Francesca Cardwell³ and Marvin Fritzler¹, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ³University of Waterloo, Waterloo, ON, Canada
Background/Purpose: At the outset of the SARS-CoV-2 pandemic, it was speculated that SLE patients may be at significant risk of developing COVID-19 due to underlying…
Abstract Number: 0088 • ACR Convergence 2021
Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data
Jeffrey Curtis¹, Xiaofeng Zhou², Jinoos Yazdany³, Philip Robinson⁴, Yan Chen², Ann Madsen², Jamie Geier² and Birgitta Benda², ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Pfizer Inc, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Patients with chronic rheumatic diseases are considered to be at increased risk for some infections, with prescribed immunomodulatory (IM) therapies increasing this risk further.…
Abstract Number: 0087 • ACR Convergence 2021
TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries
Zara Izadi¹, Erica Brenner², Satveer Mahil³, Nick Dand⁴, Zenas Yiu⁵, Mark Yates⁴, Ryan Ungaro⁶, Xian Zhang², Manasi Agrawal⁶, Jean-Frederic Colombel⁷, Milena Gianfrancesco¹, Kimme Hyrich⁵, Anja Strangfeld⁸, Loreto Carmona⁹, Elsa Frazão Mateus¹⁰, Saskia Lawson-Tovey⁵, Eva Klingberg¹¹, Giovanna Cuomo¹², Marta Caprioli¹³, Rene-Marc FLIPO¹⁴, Ana Rita Cruz-Machado¹⁵, Carolina Mazeda¹⁶, Rebecca Hasseli¹⁷, Alexander Pfeil¹⁸, Hanns-Martin Lorenz¹⁹, Laura Trupin²⁰, Stephanie Rush¹, Patricia Katz¹, Gabriela Schmajuk¹, Lindsay Jacobsohn²¹, Andrea Seet¹, Samar Al Emadi²², Leanna Wise²³, Emily Gilbert²⁴, Ali Duarte-Garcia²⁵, Maria Valenzuela-Almada²⁶, Carolina Isnardi²⁷, Rosana Quintana²⁷, Enrique Soriano²⁸, Tiffany Hsu²⁹, Kristin D'Silva³⁰, Jeffrey Sparks³¹, Naomi Patel³⁰, Viviane de Souza³², Licia Maria Henrique Mota³³, Ana Paula Reis³⁴, Zachary S. Wallace³⁵, Suleman Bhana³⁶, Wendy Costello³⁷, Rebecca Grainger³⁸, Jonathan Hausmann³⁹, Jean Liew⁴⁰, Emily Sirotich⁴¹, Paul Sufka⁴², Philip Robinson⁴³, Pedro Machado⁴⁴, Christopher Griffiths⁴⁵, Jonathan Barker⁴, Catherine smith⁴, Jinoos Yazdany¹ and Michael Kappelman², ¹University of California San Francisco, San Francisco, CA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³St John’s Institute of Dermatology, London, United Kingdom, ⁴King's College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷MD, New York, NY, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ¹⁰Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹¹University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, ¹²Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy, ¹³IRCCS Humanitas Research Hospital, Milan, Italy, ¹⁴Rheumatology Department, Lille University Hospital, Lille, France, ¹⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹⁶Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ¹⁷Justus-Liebig-University Giessen, Bad Nauheim, Germany, ¹⁸Friedrich Schiller University Jena, Jena, Germany, ¹⁹University Hospital Heidelberg Germany, Heidelberg, Germany, ²⁰UC San Francisco, San Francisco, CA, ²¹University of California San Francisco, Antioch, CA, ²²Hamad medical corporation, Doha, Qatar, ²³LAC+USC/Keck Medicine of USC, Pasadena, CA, ²⁴Mayo Clinic, Jacksonville, FL, ²⁵Mayo Clinic, Rochester, MN, ²⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ²⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²⁹Brigham and Women's Hospital, Jamaica Plain, MA, ³⁰Massachusetts General Hospital, Boston, MA, ³¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³²UFJF, JUIZ DE FORA, Brazil, ³³Universidade de Brasília, Brasilia, Brazil, ³⁴Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³⁵Harvard Medical School, Boston, MA, ³⁶Crystal Run Health, Montvale, NJ, ³⁷Irish Children's Arthritis Network, Bansha, Ireland, ³⁸University of Otago, Wellington, New Zealand, ³⁹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴⁰Boston University, Boston, MA, ⁴¹McMaster University, Hamilton, ON, Canada, ⁴²HealthPartners, Eagan, MN, ⁴³University of Queensland School of Clinical Medicine, Brisbane, Australia, ⁴⁴Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁴⁵University of Manchester, Manchester Centre for Dermatology Research, Manchester, United Kingdom
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) are widely prescribed globally due to their high efficacy across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19…
Abstract Number: 0082 • ACR Convergence 2021
Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Doruk Erkan¹, Karen Costenbader² and On Behalf of New APS Classification Criteria Development Case Collectors¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Few studies have evaluated the role of environmental factors in APS. While antiphospholipid antibodies (aPL) may be induced by environmental stiumuli, e.g., viruses, cardiovascular…
Abstract Number: 0093 • ACR Convergence 2021
The Association of General and Covid-19-Specific Stress with Changes in Patient-Reported Outcomes and Comorbidities
Patricia Katz¹, Kristin Wipfler², Sofia Pedro³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Francisco, CA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: We previously showed that perceived stress during the COVID-19 pandemic was associated with concomitant increases in symptoms of depression and anxiety. In lupus alone,…
Abstract Number: 0092 • ACR Convergence 2021
Clinical Outcomes of Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 at a Large Academic Center in New York City
Caroline Siegel¹, Jacky Choi², Debra D'Angelo², Paul Christos², Lindsay Lally¹, Parag Goyal², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: While patients with systemic rheumatic diseases (SRDs) are in general more vulnerable to infections due to their underlying immune dysregulation and immunomodulatory therapies, data…
Abstract Number: 0090 • ACR Convergence 2021
Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial
Sebastián C Rodriguez-García¹, Isidoro Gonzalez-Alvaro¹, Francisco Abad-Santos², Azucena Bautista-Hernández³, Lucio García-Fraile³, Juan Pablo Baldivieso-Achá⁴, Jesús Sanz-Sanz³ and Rosario Garcia de Vicuña¹, ¹Rheumatology Service. La Princesa University Hospital, Madrid, Spain, ²Clinical Pharmacology Service. Clinical Research and Clinical Trials Unit. La Princesa University Hospital, Madrid, Spain, ³Division of Infectious Diseases, Internal Medicine Service. La Princesa University Hospital, Madrid, Spain, ⁴Rheumatology Department. La Princesa University Hospital, Madrid, Spain
Background/Purpose: Many uncertainties remain for IL-6 blockers on the management of COVID-19 such as the optimal time of intervention, the schedule of administration and predictors…
Abstract Number: 0094 • ACR Convergence 2021
Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City
Caroline Siegel¹, Jacky Choi², Debra D'Angelo², Paul Christos², Lindsay Lally¹, Parag Goyal², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Patients with systemic rheumatic diseases (SRD) are potentially at increased risk of severe outcomes from SARS-CoV-2 infection due to their underlying immune dysregulation and…
Abstract Number: 0096 • ACR Convergence 2021
The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study
Gabriella Maioli¹, Ennio Giulio Favalli², Elisa Pesce³, Martina Biggioggero², Mauro Bombaci³, Elena Agape², Martina Martinovic³, Tanya Fabbris³, Elena Zagato³, Andrea Favalli³, Andrea Gobbini³, Sergio Abrignani³, Renata Grifantini³ and Roberto Caporali⁴, ¹Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Milan, Italy, Milan, Italy, ²ASST Gaetano Pini-CTO Institute, Division of Clinical Rheumatology, Milan, Italy, Milan, Italy, ³Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy, ⁴Policlinico S. Matteo University, Pavia, Italy
Background/Purpose: Observational data have shown that rheumatic patients seem not to be more susceptible to SARS-CoV-2 infection neither to worse outcomes. However, the true prevalence…
Abstract Number: 0095 • ACR Convergence 2021
Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Jonah Levine¹, Huong Do¹, Jessica Gordon¹, Vivian Bykerk² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: COVID-19 ‘long-haulers’ are individuals who experience persistent symptoms after COVID-19 diagnosis. Whether this is of particular concern for rheumatic disease patients, due to their…
Abstract Number: 0091 • ACR Convergence 2021
Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort
Ioana Andreica, Iulia Roman, Xenofon Baraliakos, Juergen Braun and Uta Kiltz, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) are often not adequately protected against infectious diseases. As shown in an earlier study, less than…
Abstract Number: 0085 • ACR Convergence 2021
Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes
Naomi Patel¹, Kristin D'Silva¹, Tiffany Hsu², Michael Di Iorio³, Xiaoqing Fu¹, Claire Cook⁴, Lauren Prisco⁵, Lily Martin⁶, Kathleen Vanni⁶, Alessandra Zaccardelli⁶, Yuqing Zhang⁷, Jeffrey Sparks⁶ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Quincy, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with immune-mediated diseases have similar risk of severe COVID-19 versus the general population but CD20 inhibitor users may be at increased risk of…
Abstract Number: 0066 • ACR Convergence 2021
Characterization of αβTCR of HLA-B*27-Restricted CD8 T-Cell Clones Associated with Spondyloarthropathies
Jose Garrido-Mesa¹, Nicholas Harvey², Aimee Hanson³, Tony Kenna⁴, Chi Wong⁵, Charles Bridgewood⁵, Dennis McGonagle⁵ and Matthew Brown¹, ¹King's College London, London, United Kingdom, ²Molecular Genetics, London, United Kingdom, ³University of Queensland, Brisbane, Australia, ⁴Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, ⁵University of Leeds, Leeds, United Kingdom
Background/Purpose: The mechanism by which HLA-B27 induces Ankylosing Spondylitis (AS) and related disease is unknown, but a leading hypothesis is that it presents ‘arthritogenic epitopes’…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].